Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clinical research in cardiology : official journal of the German Cardiac Society Weber, M. A., Schmieder, R. E., Kandzari, D. E., Townsend, R. R., Mahfoud, F., Tsioufis, K., Kario, K., Pocock, S., Tatakis, F., Ewen, S., Choi, J. W., East, C., Lee, D. P., Ma, A., Cohen, D. L., Wilensky, R., Devireddy, C. M., Lea, J. P., Schmid, A., Fahy, M., Bohm, M. 2022


The SPYRAL HTN-OFF MED Pivotal trial ( https://clinicaltrials.gov/ct2/show/NCT02439749 ) demonstrated significant reductions in blood pressure (BP) after renal denervation (RDN) compared to sham control in the absence of anti-hypertensive medications. Prior to the 3-month primary endpoint, medications were immediately reinstated for patients who met escape criteria defined as office systolic BP (SBP)=180mmHg or other safety concerns. Our objective was to compare the rate of hypertensive urgencies in RDN vs. sham control patients. Patients were enrolled with office SBP=150 and<180mmHg, office diastolic BP (DBP)=90mmHg and mean 24h SBP=140 and<170mmHg. Patients had been required to discontinue any anti-hypertensive medications and were randomized 1:1 to RDN or sham control. In this post-hoc analysis, cumulative incidence curves with Kaplan-Meier estimates of rate of patients meeting escape criteria were generated for RDN and sham control patients. There were 16 RDN (9.6%) and 28 sham control patients (17.0%) who met escape criteria between baseline and 3months. There was a significantly higher rate of sham control patients meeting escape criteria compared to RDN for all escape patients (p=0.032), as well as for patients with a hypertensive urgency with office SBP=180mmHg (p=0.046). Rate of escape was similar between RDN and sham control for patients without a measured BP exceeding 180mmHg (p=0.32). In the SPYRAL HTN-OFF MED Pivotal trial, RDN patients were less likely to experience hypertensive urgencies that required immediate use of anti-hypertensive medications compared to sham control.

View details for DOI 10.1007/s00392-022-02064-5

View details for PubMedID 35852582